SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

• Published in: Cancer discovery Vol. 13; no. 8; pp. 1789 - 1801
• Main Authors: Drilon, Alexander, Sharma, Manish R, Johnson, Melissa L, Yap, Timothy A, Gadgeel, Shirish, Nepert, Dale, Feng, Gang, Reddy, Micaela B, Harney, Allison S, Elsayed, Mohamed, Cook, Adam W, Wong, Christina E, Hinklin, Ronald J, Jiang, Yutong, Brown, Eric N, Neitzel, Nickolas A, Laird, Ellen R, Wu, Wen-I, Singh, Anurag, Wei, Ping, Ching, Keith A, Gaudino, John J, Lee, Patrice A, Hartley, Dylan P, Rothenberg, S Michael
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 04.08.2023
• Subjects: Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Oncogenes; Patient-Centered Care; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins - genetics; Research Brief
• ISSN: 2159-8274; 2159-8290
• DOI: 10.1158/2159-8290.CD-23-0361

Rationally targeted therapies have transformed cancer treatment, but many patients develop resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various oncogenic drivers. Activity in this setting was confirmed in diverse tumor models. Patients with ALK fusion-positive lung cancer, BRAFV600E-mutant colorectal cancer, KRASG12D-mutant ovarian cancer, and ROS1 fusion-positive pancreatic cancer who previously developed targeted therapy resistance were treated with PF-07284892 on the first dose level of a first-in-human clinical trial. After progression on PF-07284892 monotherapy, a novel study design allowed the addition of oncogene-directed targeted therapy that had previously failed. Combination therapy led to rapid tumor and circulating tumor DNA (ctDNA) responses and extended the duration of overall clinical benefit. PF-07284892-targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda, p. 1762. This article is highlighted in the In This Issue feature, p. 1749.